Relation of mortality of primary angioplasty during acute myocardial infarction to door-to-Thrombolysis In Myocardial Infarction (TIMI) time


      For primary angioplasty of acute myocardial infarction (AMI), the relation of treatment benefit and time has been debated. The present study aimed to evaluate, in a single-center cohort of patients with ST-segment elevation AMI, which time intervals were carefully and consistently measured, and the relations among ischemic time, in-hospital delays, and in-hospital survival. We included 499 patients (mean age 59 years; 80% men) who underwent successful primary percutaneous transluminal coronary angioplasty (PTCA) for AMI admitted ≤6 hours after symptom onset. The population was divided into tertiles with respect to time between onset of symptoms and admission, onset of symptoms to Thrombolysis In Myocardial Infarction (TIMI) grade 3 flow, and time from admission to TIMI grade 3 flow. Univariate analysis followed by multiple logistic regression was performed using the variables linked to mortality in the univariate analysis to assess the relation between predictor variables and in-hospital mortality. The in-hospital mortality rate was 3.2%. There was no significant relation between the various tertiles of time intervals and in-hospital mortality. After linear logistic regression, only age (odds ratio [OR] 1.79 per 10 years), female gender (OR 3.56), and door-to-TIMI 3 time (OR 1.27 per 15 minutes) were independently correlated with in-hospital mortality.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Fibrinolytic Therapy Trialist’s Collaborative Group
        Indications for fibrinolytic therapy in suspected acute myocardial infarction.
        Lancet. 1994; 343: 311-322
        • Cannon C.P.
        • Gibson C.M.
        • Lambrew C.T.
        • Shoultz D.A.
        • Levy D.
        • French W.J.
        • Gore J.M.
        • Weaver W.D.
        • Rogers W.J.
        • Tiefenbrunn A.J.
        Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction.
        JAMA. 2000; 283: 2941-2947
        • Berger P.B.
        • Bell M.R.
        • Holmes D.R.
        • Gersh B.J.
        • Hopfenspirger M.
        • Gibbons R.
        Time to reperfusion with direct coronary angioplasty and thrombolytic therapy in acute myocardial infarction.
        Am J Cardiol. 1994; 73: 231-236
        • Brodie B.R.
        • Stuckey T.D.
        • Wall T.C.
        • Kissling G.
        • Hansen C.J.
        • Muncy D.B.
        • Weintraub R.A.
        • Kelly T.A.
        Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction.
        J Am Coll Cardiol. 1998; 32: 1312-1319
        • Ward M.R.
        • Lo S.T.
        • Herity N.A.
        • Lee D.P.
        • Yeung A.C.
        Effect of audit on door-to-inflation times in primary angioplasty/stenting for acute myocardial infarction.
        Am J Cardiol. 2001; 87: 336-338
      1. Ferguson JJ. DANAMI II Danish Multicenter Randomized Study on Thrombolytic Therapy Versus Acute Coronary Angioplasty in Acute Myocardial Infarction-2. Meeting Highlights. Highlights of the 51st Annual Scientific Sessions of the American College of Cardiology. Circulation 2002;106:e24

        • Grines C.L.
        • Westerhausen D.R.
        • Grines L.L.
        • Hanlon J.T.
        • Logemann T.L.
        • Niemela M.
        • Weaver W.D.
        • Graham M.
        • Boura J.
        • O’Neill W.W.
        • Balestrini C.
        • AIR PAMI Study Group
        A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction. The Air Primary Angioplasty in Myocardial Infarction Study.
        J Am Coll Cardiol. 2002; 39: 1713-1719
        • Aversano T.
        • Aversano L.T.
        • Passamani E.
        • Knatterud G.L.
        • Terrin M.L.
        • Williams D.O.
        • Foreman S.A.
        • Atlantic Cardiovascular Patient Outcomes Research Team (C-PORT)
        Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery. A randomized controlled trial.
        JAMA. 2002; 287: 1943-1951
        • Widimsky P.
        • Groch L.
        • Zelizko M.
        • Aschermann M.
        • Bednar S.
        • Suryapranata H.
        • PRAGUE Study Group Investigators
        Multicenter randomized trial comparing transport to primary angioplasty versus immediate thrombolysis versus combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory.
        Eur Heart J. 2002; 21: 823-831
        • Thiemann D.R.
        • Coresh J.
        • Oetgen W.J.
        • Powe N.R.
        The association between hospital volume and survival after acute myocardial infarction in elderly patients.
        N Engl J Med. 1999; 340: 1640-1648
        • Vakili B.A.
        • Kaplan R.
        • Brown D.L.
        Volume-outcome relation for physicians and hospitals performing angioplasty for acute myocardial infarction in New York state.
        Circulation. 2001; 104: 2171-2176
        • Juliard J.M.
        • Himbert D.
        • Golmard J.L.
        • Aubry P.
        • Karrillon G.J.
        • Boccara A.
        • Benamer H.
        • Steg P.G.
        Can we provide reperfusion therapy to all unselected patients admitted with acute myocardial infarction?.
        J Am Coll Cardiol. 1997; 30: 157-164
        • Chesebro J.H.
        • Knatterud G.
        • Roberts R.
        • Borer J.
        • Cohen L.S.
        • Dalen J.
        • Dodge H.T.
        • Francis C.K.
        • Hillis D.
        • Ludbrook P.
        • et al.
        Thrombolysis In Myocardial Infarction (TIMI) trial, phase I.
        Circulation. 1987; 76: 142-154
        • Lee K.L.
        • Woodlief L.H.
        • Topol E.J.
        • Weaver W.D.
        • Betriu A.
        • Col J.
        • Simoons M.L.
        • Aylward P.
        • Van de Werf F.
        • Califf R.M.
        • GUSTO-I Investigators
        Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41 021 patients.
        Circulation. 1995; 91: 1659-1668
        • O’Keefe Jr, J.H.
        • Bailey W.L.
        • Rutherford B.D.
        • Hartzler G.O.
        Primary angioplasty for acute myocardial infarction in 1,000 consecutive patients. Results in an unselected population and high-risk subgroups.
        Am J Cardiol. 1993; 72: 107G-115G
        • Berger P.B.
        • Ellis S.G.
        • Holmes D.R.
        • Granger C.B.
        • Griger D.A.
        • Betriu A.
        • Topol E.J.
        • Califf R.M.
        • GUSTO-II Investigators
        Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction. Results from the Global Use of Strategies to Open Occluded Arteries In Acute Coronary Syndromes (GUSTO-IIb) Trial.
        Circulation. 1999; 100: 14-23
        • Steg P.G.
        • Laperche T.
        • Golmard J.L.
        • Juliard J.M.
        • Benamer H.
        • Himbert D.
        • Aubry P.
        • PERM Study Group
        Efficacy of streptokinase but not tissue-plasminogen activator in achieving 90-minute, patency after thrombolysis for acute myocardial infarction decreases with time to treatment.
        J Am Coll Cardiol. 1998; 31: 776-779
        • Newby L.K.
        • Rutsch W.R.
        • Califf R.M.
        • Simoons M.L.
        • Aylward T.E.
        • Armstrong P.W.
        • Woodlief L.H.
        • Lee K.L.
        • Topol E.J.
        • Van de Werf F.
        • GUSTO-I Investigators
        Time from symptom onset to treatment and outcomes after thrombolytic therapy.
        J Am Coll Cardiol. 1996; 27: 1646-1655
        • Reimer K.A.
        • Jennings R.B.
        The “wavefront phenomenon” of myocardial ischemic cell death, II.
        Lab Invest. 1979; 40: 633-644
        • Braunwald E.
        Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival.
        Circulation. 1989; 70: 441-444
        • McGrath P.D.
        • Wennberg D.E.
        • Malenka D.J.
        • Kellett M.A.
        • Ryan T.J.
        • O’Meara J.R.
        • Bradley W.A.
        • Hearne M.J.
        • Hettleman B.
        • Robb J.F.
        • et al.
        for the Northern New England Cardiovascular Disease Study Group. Operator volume and outcomes in 12,988 percutaneous coronary interventions.
        J Am Coll Cardiol. 1998; 31: 570-576
        • Tu J.V.
        • Austin P.C.
        • Chan B.T.B.
        Relationship between annual volume of patients treated by admitting physicians and mortality after acute myocardial infarction.
        JAMA. 2001; 285: 3116-3122
        • Ryan T.J.
        • Antman E.M.
        • Brooks N.H.
        • Califf R.M.
        • Hillis L.D.
        • Hiratzka L.F.
        • Rapaport E.L.
        • Riegel B.
        • Russell R.O.
        • Smith III, E.E.
        • Weaver D.W.
        1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction.
        Circulation. 1999; 100: 1016-1030
        • Meyer P.
        • Barragan P.
        • Blanchard D.
        • Chevalier B.
        • Commeau P.
        • Danchin N.
        • Fajadet J.
        • Grand A.
        • Lablanche J.M.
        • Machecourt J.
        • et al.
        Recommandations de la Société Française de Cardiologie concernant la formation des médecins coronarographistes et angioplasticiens l’organisation et l’équipement des centres de coronarographie et d’angioplastie coronaire.
        Arch Mal Cœur. 2000; 93: 147-158